Novavax (NASDAQ:NVAX) 株価情報

NOVAVAX INC

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

これらの中型株は直近1週間で最も好調のパフォーマンスを示しました。あなたのポートフォリオには入っていますか？

直近1週間高パフォーマンスを示したのは、中型株

Novavax Inc

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock moved upwards by 81.6% to $0.62 during Thursday's regular session. The market value of their outstanding shares is at $2.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 66.42% to $0.02. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock rose 50.58% to $0.93. The market value of their outstanding shares is at $8.9 million. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock increased by 38.04% to $311.01. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 33.99% to $1.46. The market value of their outstanding shares is at $3.9 million. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock increased by 27.67% to $3.93. The market value of their outstanding shares is at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares fell 52.8% to $4.22 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) stock declined by 24.78% to $1.24. The company's market cap stands at $112.6 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares declined by 21.76% to $0.87. The company's market cap stands at $4.9 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 21.2% to $5.32. The market value of their outstanding shares is at $855.5 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 21.12% to $0.13. The market value of their outstanding shares is at $6.0 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares declined by 19.59% to $4.08. The company's market cap stands at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

BNGO

DHAI

KTTA

LUCD

NDRA

RSLS

STSS

VERO

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Novavax shares are trading lower following comments by RFK Jr. on the company's COVID-19 vaccine in an interview.

<a href="https://www.bloomberg.com/news/articles/2025-04-10/novavax-shares-plunge-after-rfk-jr-questions-its-covid-vaccine" title="https://www.bloomberg.com/news/articles/2025-04-10/novavax-shares-plunge-after-rfk-jr-questions-its-covid-vaccine">https://www.bloomberg.com/news/articles/2025-04-10/novavax-shares-plunge-after-rfk-jr-questions-its-covid-vaccine</a>

'Novavax Shares Plunge After RFK Jr. Questions Its Covid Vaccine' - Bloomberg News

Bank of America Securities <a href="https://www.benzinga.com/general/biotech">writes that SMid-cap biotech</a>, companies with small to mid-sized market capitalizations, had a rocky start to the year.
Many companies in the coverage are down 20-40% year-to-date (NBI: -2.35%).
Tariff concerns and the U.S. Food and Drug Administration (FDA) shakeup added further near-term uncertainty to an already challenging <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">already challenging outlook</a>.
Earlier this week, Peter Marks resigned from his role at the FDA&#8217;s Center for Biologics Evaluation and Research.
Marks was a top regulator at the FDA and played a key role in ensuring the quick approval of vaccines <a href="https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on" target="_blank" rel="noreferrer noopener">during the COVID-19 pandemic</a>.
In March, the U.S. Department of Health and Human Services unveiled a sweeping restructuring plan on Thursday to cut costs, streamline operations and refocus priorities.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage" rel="noreferrer noopener">FTC Pauses Lawsuit Against CVS, Cigna, UnitedHealth&#8217;s PBMs Amid Commissioner Shortage</a>
The changes, aligned with President&nbsp;Donald Trump's&nbsp;executive order on government efficiency, will reduce the agency&#8217;s workforce, consolidate divisions, and emphasize efforts to <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44519638/us-department-of-health-and-human-services-aligns-with-trumps-executive-order-to-cut-10k-jobs-save-18-billion" rel="noreferrer noopener">combat chronic illness</a>.
The analyst points out that public biotech companies raised only $4.7 billion, compared to $13.6 billion last year, highlighting ongoing challenges in the capital market.
&#8220;And while we see these macro headwinds as likely to continue over the course of 2025, <a href="https://www.benzinga.com/markets/25/04/44627820/trumps-reciprocal-tariffs-on-india-exempt-pharma-easing-mark-cubans-price-hike-concerns">drugs being exempt from reciprocal tariffs</a> should offer some much-needed near-term reprieve for the sector, in our view,&#8221; BofA analyst writes.
Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) is just one example of FDA. On Wednesday, the regulators missed the deadline for deciding to grant full approval to Novavax&#8217;s Covid-19 shot.
BofA expects more details on the delay in the coming weeks. The expected $125 million milestone payment from Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) will likely be pushed to the second half of 2025.
Despite small and mid-cap biotech stocks being among the worst performers this year, the sector may still present a strong opportunity. Most of these companies (80%) are pre-commercial and have minimal exposure to tariffs or FDA decisions, with only 2 out of 29 under BofA coverage awaiting FDA approval.
The bigger challenges are high interest rates and limited access to capital, but these risks are already factored into valuations. While negative headlines may continue to impact sentiment and investment flows, the recent broad sell-off could be an appealing entry point.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/04/44630746/serve-robotics-and-uber-eats-launch-self-driving-delivery-service-in-uptown-dallas" target="_blank" rel="noreferrer noopener">Serve Robotics and Uber Eats Launch Self-Driving Delivery Service in Uptown Dallas</a></li>
</ul>
Image: Shutterstock

Analyst Color

Biotech

Health Care

Analyst Ratings

General

Despite Headwinds, Biotech Sell-Off Could Offer Buying Opportunity: Analyst

Editor&#8217;s Note: The story has been updated with comments from Novavax
In September 2024, the U.S. Food And Drug Administration (FDA) granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in <a href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" target="_blank" rel="noreferrer noopener">individuals aged 12 and older</a>.
Novavax's vaccine was included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on&nbsp;June 27, 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million" rel="noreferrer noopener">Wegovy Maker Novo Nordisk To Buy Novavax&#8217;s Czech Republic Manufacturing Facility For $200 Million</a>
According to a media report on Wednesday, the regulators missed the deadline for deciding to grant full approval to Novavax's shot.
In an emailed statement to Benzinga, Novavax said, &#8220;Novavax can confirm that April 1, 2025, was the U.S. Food and Drug Administration (FDA)'s Prescription Drug User Fee Act date for our Biologics License Application (BLA) seeking the approval of our COVID-19 Vaccine. As of Tuesday, April 1, we had responded to all of the FDA's information requests and we believe that our BLA is ready for approval. 
As of today, we continue to wait on action from the agency and have not yet received an official decision from the U.S. FDA. Our application included robust Phase 3 clinical trial data that showed our vaccine is safe and effective for the prevention of COVID-19. We are confident our well-tolerated vaccine represents an important alternative to mRNA COVID-19 vaccines for the U.S.&#8221;
Earlier this week, Peter Marks&nbsp;resigned from his role at the FDA's Center for Biologics Evaluation and Research.
Marks was a top regulator at the FDA and played a key role in pushing quick approvals of vaccines <a href="https://www.benzinga.com/25/03/44562368/moderna-novavax-shares-are-tumbling-monday-whats-going-on" target="_blank" rel="noreferrer noopener">during the COVID-19 pandemic</a>.
The Wall Street Journal <a href="https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b" target="_blank" rel="noreferrer noopener">writes</a> that the agency is now delaying the decision and has reportedly asked for more data and that the application isn't likely to be approved soon, according to sources.
The FDA set an April 1 deadline for a decision.
Novavax reported fourth-quarter 2024 sales of $88.31 million, compared to&nbsp;$291 million&nbsp;a year, beating the&nbsp;consensus of $84.35 million. The decrease was due to lower product sales <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/44013531/novavax-reports-smaller-q4-loss-shifts-focus-from-commercializing-covid-19-vaccine-to-maximize-value" rel="noreferrer noopener">under APA agreements</a>.
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44004179/novavax-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights" rel="noreferrer noopener">with the Wall Street Estimate</a>.
The news comes after vaccine stocks came under pressure last week following reports that the Trump administration plans to end financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. The Trump administration reportedly plans to cut billions in global health initiatives.
Price Action: NVAX stock is up 1.25% at $6.09 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44610702/edgewise-therapeutics-sees-meaningful-hcm-treatment-gains-with-edg-7500-in-phase-2-study" target="_blank" rel="noreferrer noopener">Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study</a></li>
</ul>
Photo: Shutterstock

Rumors

FDA Delays Full Approval Decision On Novavax's COVID-19 Vaccine (UPDATED)

<a href="https://ir.novavax.com/press-releases/Update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine" title="https://ir.novavax.com/press-releases/Update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine">https://ir.novavax.com/press-releases/Update-on-U-S-FDA-BLA-for-Novavaxs-COVID-19-Vaccine</a>

Novavax Confirms That April 1, 2025, Was The U.S. FDA's Prescription Drug User Fee Act Date For It's Biologics License Application Seeking The Approval Its COVID-19 Vaccine

<a href="https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b" title="https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b">https://www.wsj.com/health/healthcare/fda-novavax-covid-19-vaccine-deadline-c160454b</a>

'FDA Misses Deadline For Covid-19 Vaccine Decision' - Wall Street Journal

Politics

CVAC

MRNA

Trump Administration Health Agency Firings Include Staff Overseeing Bird Flu Response

Vaccine stocks are trading lower Monday following a shakeup at the <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">U.S. Food and Drug Administration</a>.
What Happened: Peter Marks has resigned from his role at the FDA&#8217;s Center for Biologics Evaluation and Research. According to a Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-03-31/vaccine-makers-plunge-after-fda-biologics-head-marks-steps-down?srnd=homepage-uk&amp;embedded-checkout=true"> report</a>, Marks was a top regulator at the FDA and played a key role in pushing quick approvals of vaccines during the Covid pandemic. 
Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares were down 13.5% at $26.88 and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares were down 9.6% at $6.30 at last check. The SPDR S&amp;P Biotech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XBI#NYSE">XBI</a>) was down about 5.76% at publication time, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The report indicates that Marks was also responsible for the FDA&#8217;s evaluation of cutting-edge treatments like cell therapies and gene therapies. He reportedly cited some issues with Health and Human Services Secretary Robert F. Kennedy Jr. in his resignation letter.
"I was willing to work to address the Secretary's concerns regarding vaccine safety and transparency," Marks reportedly said in the letter. 
"However it has become clear that truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies."
Check This Out: <a href="https://www.benzinga.com/25/03/44560524/auto-stocks-skid-after-trump-shrugs-off-higher-prices-should-you-buy-the-dip">Auto Stocks Skid After Trump Shrugs Off Higher Prices &#8211; Should You Buy The Dip?</a>
The news comes after vaccine stocks came under pressure last week following reports The Trump administration plans to end financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. The Trump administration reportedly plans to cut billions in global health initiatives. 
Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was reportedly&nbsp;<a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight" target="_blank" rel="noreferrer noopener">reconsidering that funding</a>&nbsp;as of last month.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/insights/options/25/03/44518123/modernas-options-frenzy-what-you-need-to-know">Moderna&#8217;s Options Frenzy: What You Need to Know</a></li>
</ul>
Photo: Shutterstock.

Moderna, Novavax Shares Are Tumbling Monday: What's Going On?

Vaccine makers Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) and Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are facing selling pressure on Wednesday following reports suggesting the Trump administration will <a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44495713/the-trump-administration-intends-to-terminate-u-s-financial-support-for-gavi-and-">end support for Gavi</a>.
What To Know: According to a New York Times <a href="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html">report</a>, The Trump administration plans to cease financial support for vaccine alliance Gavi, which helps buy vaccines for children in developing countries. 
The Trump administration is also planning to &#8220;significantly scale back&#8221; support for efforts to combat malaria, the report states, citing a document from the United States Agency for International Development.
Meanwhile, the administration will continue to provide some grants for H.I.V. and tuberculosis medications, as well as food aid for countries in civil wars or facing natural disasters. In total, the Trump administration has reportedly decided to end 5,341 previously granted awards and continue with 898 of them. 
See Also: <a href="https://www.benzinga.com/insights/options/25/03/44422820/modernas-options-a-look-at-what-the-big-money-is-thinking">Moderna&#8217;s Options: A Look at What the Big Money is Thinking</a>
Funding for the United Nations Food and Agriculture Organization is also being terminated. The report indicates that the organization conducts surveillance for diseases that can be transmitted from animals to humans, including the bird flu. 
Moderna was awarded $590 million by the U.S. Department of Health and Human Services (HHS) in January to continue developing a vaccine to protect against bird flu. The Trump administration was reportedly <a href="https://www.benzinga.com/25/02/43999106/trumps-officials-to-re-consider-modernas-590-million-bird-flu-vaccine-funding-hhs-cites-biden-administrations-failed-oversight">reconsidering that funding</a> as of last month. 
MRNA, NVAX Price Action: At the time of publication, Moderna shares were down 5.70% at $31.91 and Novavax shares were down 3.37% at $7.30, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Global

Moderna, Novavax Shares Are Sliding Wednesday: What's Going On?

BNTX

Shares of vaccine stocks are trading lower on reports suggesting the Trump Administration will end support for vaccine alliance, Gavi.

<a href="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C" title="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C">https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C</a>

Macro Economic Events

Economics

'The Trump Administration Intends To Terminate U.S. Financial Support For Gavi And To Significantly Scale Back Support For Efforts To Combat Malaria' - NY Times

Novavax shares are trading higher after the company reported better-than-expected Q4 revenue results.

Stocks recovered on Friday, with all three major indexes in the green, as the tech sector bounced back from Thursday's losses with NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) up 1.37% and Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/trading-ideas/technicals/25/02/44043021/tesla-the-only-magnificent-seven-stock-in-freefall-can-it-reverse-course">rising 2.71%.&nbsp;</a>
PCE data released before<a href="https://www.benzinga.com/news/econ-s/25/02/44041803/federal-reserves-preferred-inflation-gauge-marks-first-slowdown-in-4-months"> the opening bell</a> also provided some relief to investors as the price index marked its first decline in four months. Data from the CME FedWatch Tool shows the data reinforced bets for approximately two quarter-point cuts to the Fed funds rate in 2025. 
Read More: <a href="https://www.benzinga.com/news/econ-s/25/02/44041803/federal-reserves-preferred-inflation-gauge-marks-first-slowdown-in-4-months">Federal Reserve&#8217;s Preferred Inflation Gauge Marks First Slowdown In 4 Months (UPDATED)</a>
The yield on the 10-year U.S. Treasury note was down to 4.25% on Friday, after falling more than 15bps this week to its lowest level in over two months. Personal spending unexpectedly slipped in January while income soared, and tariff concerns continued to weigh against prospective future growth. 
The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.31%.&nbsp;
Cryptocurrencies continued to sell off Friday as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44048486/bitcoins-24-correction-mostly-technical-say-experts">sharp decline</a> in investor sentiment gripped the market after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell below $79,000 late Thursday, down 24% from its January peak of $109,590.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.14</td>
<td>$124.3 billion</td>
<td>-2.6%&nbsp;</td>
<td>-17.9%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin&nbsp;(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$83,826.89</td>
<td>$1.7 trillion</td>
<td>-2.1%&nbsp;</td>
<td>-14.1%&nbsp;</td>
</tr>
<tr>
<td>Ethereum&nbsp;(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,216.48</td>
<td>$267.4 billion</td>
<td>-4.7%</td>
<td>-18.2%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,635.47</td>
<td>0.48%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,887.77</td>
<td>0.45%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,455.42</td>
<td>0.50%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,152.96</td>
<td>0.62%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.49% to $587.94. &nbsp;</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) climbed 0.58% to $434.87. </li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.65% to $503.50.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.61% to $213.70.&nbsp;</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) was up 0.9% to $214.35.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.5% to $90.06.&nbsp;&nbsp;</li>
</ul>
Friday's Stock Movers:&nbsp;
Shares of vaccine-maker Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) climbed on heavy volume Friday after the company reported smaller fourth-quarter losses and announced a shift in corporate strategy away from its COVID-19 vaccine. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)&nbsp;</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>)&nbsp;</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)&nbsp;</li>
<li>Duolingo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NYSE">DUOL</a>)&nbsp;</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)&nbsp;</li>
<li>Archer Aviation Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>)&nbsp;</li>
<li>Talen Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>)&nbsp;</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>)&nbsp;</li>
<li>Edison International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>)&nbsp;</li>
</ul>
Companies reporting earnings on Monday include: 
<ul>
<li>Plug Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) </li>
<li>B. Riley Financial, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>)</li>
<li>Hut 8 Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>)</li>
<li>Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>)</li>
<li>GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>)</li>
<li>NuScale Power Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) </li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) </li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) </li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>)</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/44015237/pending-home-sales-crash-to-record-low-jobless-claims-soar-wall-street-reacts">Pending Home Sales Crash To Record Low, Jobless Claims Soar: Wall Street Reacts</a></li>
</ul>
Image: Shutterstock

Equities

Large Cap

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Markets

Tech

ETFs

$BTC

$ETH

$XRP

ACHR

ASTS

CLOV

DELL

SPDR Dow Jones Industrial Average ETF Trust

DUOL

GTLB

NOVA

OKTA

PLUG

RILY

RKLB

SOUN

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?

On Thursday,&nbsp;Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported fourth-quarter 2024 sales of $88.31 million, compared to&nbsp;$291 million&nbsp;a year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $84.35 million</a>. The decrease was due to lower product sales under APA agreements.
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n44004179/novavax-reports-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights" rel="noreferrer noopener">with the Wall Street Estimate</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42323263/wegovy-maker-novo-nordisk-to-buy-novavaxs-czech-republic-manufacturing-facility-for-200-million" rel="noreferrer noopener">Wegovy Maker Novo Nordisk To Buy Novavax&#8217;s Czech Republic Manufacturing Facility For $200 Million</a>
&#8220;In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing our COVID-19 vaccine to maximizing the value of our cutting-edge technology platform through pipeline expansion and partnerships for our development-stage vaccine candidates and our Matrix-M adjuvant,&#8221; said&nbsp;John C. Jacobs, President and Chief Executive Officer, Novavax. &#8220;As we look to 2025 and beyond, we believe we are well positioned to potentially create significant value for all stakeholders.&#8221;
Nuvaxovid sales reached $49.8 million, down from $251.5 million a year ago. The company ended 2024 with over&nbsp;$1 billion&nbsp;in cash and accounts receivables.
Novavax has transitioned the lead commercial responsibility of Nuvaxovid to Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) for select markets beginning with the 2025-<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38758287/some-breather-for-novavaxs-covid-19-vaccine-inks-multibillion-dollar-deal-with-sanofi-and-erases-" rel="noreferrer noopener">2026 vaccination season</a>.
Since Novavax is reliant on Sanofi&#8217;s sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time.
Novavax expects to achieve adjusted licensing, royalties, and other revenue of between&nbsp;$300 million&nbsp;and $350 million in 2025. Novavax is eligible to receive royalties in the high teens to low twenties percent on Sanofi sales.
<h2 class="wp-block-heading">Novavax Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Novavax have an average 1-year price target of $19.0, representing an expected upside of 141.41%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Novavax, while 1 analysts have bullish ratings. The street high price target from HC Wainwright &amp; Co. is $19.0, while the street low from HC Wainwright &amp; Co. is $19.0.
Price Action: NVAX stock is up 10.4% at $8.08 at the last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/44010386/why-is-ad-giant-wpp-stock-falling-today" target="_blank" rel="noreferrer noopener">Why Is Ad Giant WPP Stock Falling Today?</a></li>
</ul>

Earnings

Guidance

Trading Ideas

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Full Year 2025 Financial Guidance&nbsp;
Novavax is providing Full Year 2025 Financial Guidance for R&amp;D plus SG&amp;A expenses and expects to achieve the following results:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">$ in millions</td>
<td colspan="1" rowspan="1">
Full Year 2025
(as of February 27, 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Combined R&amp;D and SG&amp;A Expenses</td>
<td colspan="1" rowspan="1">$475 - $525</td>
</tr>
</tbody>
</table>
</figure>
2025 Revenue Framework
Novavax has transitioned lead commercial responsibility of Nuvaxovid beginning with the 2025-2026 vaccination season to Sanofi for select markets. Since Novavax is reliant on Sanofi's sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time. For 2025, Novavax expects to achieve Adjusted Licensing, Royalties and Other Revenue of between $300 million to $350 million.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">$ in millions</td>
<td colspan="1" rowspan="1">
Full Year 2025
(as of February 27, 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sanofi Royalties</td>
<td colspan="1" rowspan="1">No guidance at this time</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Sanofi CIC and Matrix-M Milestones</td>
<td colspan="1" rowspan="1">No guidance at this time</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Product Sales</td>
<td colspan="1" rowspan="1">No guidance at this time</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Licensing, Royalties and Other Revenue 1.2,3,4,5</td>
<td colspan="1" rowspan="1">$300 - $350</td>
</tr>
</tbody>
</table>
</figure>

For 2025, Novavax Expects To Achieve Adjusted Licensing, Royalties And Other Revenue Of Between $300M-$350M, Ended Full Year 2024 With Over $1B In Cash And Accounts Receivables

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported quarterly losses of $(0.51) per share which met the analyst consensus estimate. This is a 65.31 percent increase over losses of $(1.47) per share from the same period last year. The company reported quarterly sales of $88.31 million which beat the analyst consensus estimate of $84.38 million by 4.66 percent. This is a 69.69 percent decrease over sales of $291.34 million the same period last year.

Novavax Q4 2024 GAAP EPS $(0.51), Inline, Sales $88.31M Beat $84.38M Estimate

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported quarterly losses of $(1.23) per share which beat the analyst consensus estimate of $(1.32) by 6.82 percent. This is a 77.26 percent increase over losses of $(5.41) per share from the same period last year. The company reported quarterly sales of $682.16 million which missed the analyst consensus estimate of $684.94 million by 0.41 percent. This is a 30.65 percent decrease over sales of $983.71 million the same period last year.

Novavax FY 2024 GAAP EPS $(1.23) Beats $(1.32) Estimate, Sales $682.16M Miss $684.94M Estimate

AAON

ABCL

ACEL

ACHC

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-02262025.html#:~:text=As%20of%20February%2024%2C%20CDC,backyard%20poultry%20flock%20(Wyoming).</a>
&nbsp;
<h2>Situation Update</h2>
February 26, 2025 &ndash; CDC continues to respond to the public health challenge posed by a multistate outbreak of avian influenza A(H5N1) virus, or &quot;H5N1 bird flu,&quot; in dairy cows, poultry, and other animals in the United States. CDC is working in collaboration with the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA), Administration for Strategic Preparedness and Response (ASPR), state public health and animal health officials, and other partners using a <a href="https://www.cdc.gov/one-health/about/index.html">One Health approach</a>.

CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website

Press Releases

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million

Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza

Contracts

Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone

Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025

Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Comments

Novavax

ニュース

パートナーシップ

ベンジンガ・グローバル